Abbott Laboratories (NYSE:ABT) Research Coverage Started at Barclays

Barclays started coverage on shares of Abbott Laboratories (NYSE:ABT) in a research report report published on Wednesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $120.00 price objective on the healthcare product maker’s stock.

Other equities research analysts have also issued reports about the stock. TD Cowen reissued a “buy” rating and issued a $135.00 target price on shares of Abbott Laboratories in a report on Tuesday, September 8th. Piper Sandler reiterated an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. BTIG Research increased their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a research report on Thursday, August 13th. Finally, Citigroup lifted their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.88.

Abbott Laboratories Trading Up 1.2%

Shares of Abbott Laboratories stock opened at $99.71 on Wednesday. The stock has a market capitalization of $172.53 billion, a PE ratio of 32.27, a P/E/G ratio of 1.83 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company’s fifty day simple moving average is $106.25 and its 200-day simple moving average is $98.35. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $134.50.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the previous year, the company posted $1.26 earnings per share. Abbott Laboratories’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s payout ratio is 81.55%.

Hedge Funds Weigh In On Abbott Laboratories

Several institutional investors have recently added to or reduced their stakes in the company. ANB Bank increased its stake in Abbott Laboratories by 1.8% in the 3rd quarter. ANB Bank now owns 35,795 shares of the healthcare product maker’s stock worth $3,538,000 after acquiring an additional 633 shares during the last quarter. Mirador Capital Partners LP boosted its position in shares of Abbott Laboratories by 81.2% during the 3rd quarter. Mirador Capital Partners LP now owns 18,055 shares of the healthcare product maker’s stock valued at $1,784,000 after acquiring an additional 8,090 shares during the last quarter. GK Wealth Management LLC purchased a new position in shares of Abbott Laboratories in the third quarter valued at $126,000. Balefire LLC grew its holdings in shares of Abbott Laboratories by 25.4% in the third quarter. Balefire LLC now owns 6,124 shares of the healthcare product maker’s stock valued at $605,000 after purchasing an additional 1,241 shares in the last quarter. Finally, Decker Wealth Management LLC increased its position in Abbott Laboratories by 2.1% in the third quarter. Decker Wealth Management LLC now owns 14,650 shares of the healthcare product maker’s stock worth $1,448,000 after purchasing an additional 295 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.